Related Experiment Videos
Platelet-activating factor (PAF) in experimental and clinical sepsis
G Mathiak1, D Szewczyk, F Abdullah
1Department of Surgery, Thomas Jefferson University, Jefferson Medical College, Philadelphia, Pennsylvania 19107, USA.
Shock (Augusta, Ga.)
|June 1, 1997
Summary
Platelet-activating factor (PAF) plays a key role in Gram-negative sepsis pathogenesis. This review examines evidence for PAF
Area of Science:
- Immunology
- Pathophysiology
- Pharmacology
Background:
- Gram-negative sepsis remains a significant clinical challenge despite advances in understanding its mechanisms.
- Inflammatory mediators, acting alongside infectious agents, are crucial in sepsis initiation and progression.
- Platelet-activating factor (PAF) is identified as a key glycerophospholipid mediator in sepsis.
Purpose of the Study:
- To consolidate experimental and clinical evidence linking PAF to the pathomechanism of sepsis.
- To provide a timely analysis of PAF's role given the development of PAF antagonists for clinical trials.
Main Methods:
- Review of existing experimental data on PAF in sepsis models.
- Analysis of clinical evidence implicating PAF in septic patients.
- Evaluation of the therapeutic potential of PAF antagonists.
Main Results:
- Experimental studies demonstrate PAF's involvement in sepsis-induced inflammation and organ damage.
- Clinical data suggest elevated PAF levels correlate with sepsis severity and poor outcomes.
- PAF antagonists have shown promise in preclinical models, warranting further clinical investigation.
Conclusions:
- PAF is a critical mediator in the pathogenesis of Gram-negative sepsis.
- Targeting PAF with antagonists represents a potential therapeutic strategy for sepsis.
- Further clinical evaluation of PAF antagonists is essential for academic and pharmaceutical development.